Eledon Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 09/30/24 | FY 06/30/24 | FY 03/31/24 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $66.3M | $52.0M | — | — | — |
| Operating expenses | $83.3M | $70.6M | — | — | — |
| Pretax income | -$45.6M | -$35.8M | — | — | — |
| Income tax expense | $35,000 | $431,000 | — | — | — |
| Net income | -$45.6M | -$36.2M | — | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $22.8M | $20.5M | — | — | — |
| Current assets | $135.7M | $143.7M | — | — | — |
| Total assets | $169.0M | $177.4M | — | — | — |
| Current liabilities | $18.3M | $11.6M | — | — | — |
| Total liabilities | $32.2M | $59.3M | — | — | — |
| Total debt | $0 | $0 | — | — | — |
| Stockholders' equity | $81.1M | $62.4M | $20.4M | -$64.2M | -$70.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$62.3M | -$47.3M | — | — | — |
| Stock-based compensation | $10.5M | $13.1M | — | — | — |
| Impairments | — | $0 | — | — | — |
Shares outstanding 77.2M · Free float 76.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.